Selected Publications
Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Wieduwilt MJ, Liedtke M, Bergeron J, Wood BL, Zhao Y, Wu G, Chang TC, Zhang W, Pratz KW, Dinner SN, Frey N, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, DeAngelo DJ, Patel SB, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave RR, Sharon E, Little RF, Erba HP, Stone RM, Luger SM, Mullighan CG, Tallman MS: Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults N Engl J Med : 2024.
8., Wolfson JA, Grimes AC, Nuno M, Kerber CL, Ramakrishnan S, Beauchemin M, Dickens D, Levine JM, Roth ME, Scialla M, Woods W, Vargas S, Boayue KB, Chang GJ, Stock W, Hershman D, Curran E, Advani A, O'Dwyer K, Luger S, Liu JJ, Freyer DR, Sung L, Parsons SK: Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL JCO Oncol Pract. : 2024.
Laczko, Dorottya, Corey Poveda-Rogers, Andrew H. Matthews, Oraine Snaith, Selina Luger, Adam Bagg, Gabriel C. Caponetti, Jennifer J.D Morrissette, Guang Yang: RAD21 mutations in acute myeloid leukemia Leukemia & Lymphoma 65(7) (958-964): 2024.
Freyer CW, Carulli A, Frey NV, Gill SI, Hexner EO, Martin ME, Luger SM, Porter DL, Stadtmauer EA, Loren AW: Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation Leuk Lymphoma : 2024.
Sung AD, Koll T, Gier SH, Racioppi A, White G, Lew M, Free M, Agarwal P, Bohannon LM, Johnson EJ, Selvan B, Babushok DV, Frey NV, Gill SI, Hexner EO, Martin M, Perl AE, Pratz KW, Luger SM, Chao NJ, Fisher AL, Stadtmauer EA, Porter DL, Loren AW, Bhatt VR, Gimotty PA, McCurdy SR: Pre-Conditioning Frailty Phenotypes Influence Survival and Relapse for Older Allogeneic Transplantation Recipients Transplant Cell Ther : 2024.
Woyach JA, Perez Burbano GE, Ruppert AS, Miller CR, Heerema NA, Zhao W, Wall A, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Stephens DM, Brown JR, Lozanski G, Blachly JS, Nattam S, Larson RA, Erba HP, Litzow MR, Luger SM, Owen C, Kuzma C, Abramson JS, Little RF, Dinner SN, Stone RM, Uy GL, Stock W, Mandrekar SJ, Byrd JC: Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL Blood : 2024.
Garcia-Manero G, Podoltsev NA, Othus M, Pagel JM, Radich JP, Fang M, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Kolitz JE, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Appelbaum FR, Erba HP: A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML Leukemia : 2024.
10., Ilaria Iacobucci, Andy G.X. Zeng, Qingsong Gao, Laura Garcia-Prat, Pradyumna Baviskar, Sayyam Shah, Alex Murison, Veronique Voisin, Michelle Chan-Seng-Yue, Cheng Cheng, Chunxu Qu, Colin Bailey, Matthew Lear, Matthew T. Witkowski, Xin Zhou, Airen Zaldivar Peraza, Karishma Gangwani, Anjali S. Advani, Selina M. Luger, Mark R. Litzow, Jacob M Rowe, Elisabeth M. Paietta, Wendy Stock, John E. Dick, Charles G Mullighan: SINGLE CELL DISSECTION OF DEVELOPMENTAL ORIGINS AND TRANSCRIPTIONAL HETEROGENEITY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA bioRxiv : 2023.
Lyndsay N. Harris, Charles D. Blanke, Harry P. Erba, James M. Ford, Robert J. Gray, Michael L. LeBlanc, Siwen Hu-Lieskovan, Mark R. Litzow, Selina M. Luger, Funda Meric-Bernstam, Peter J. O'Dwyer, Megan K.D. Othus, Katerina Politi, Lois E. Shepherd, Carmen J. Allegra, Helen X. Chen, S. Percy Ivy, Larissa A. Korde, Richard F. Little, Lisa M. McShane, Jeffrey A. Moscow, David R. Patton, Magdalena Thurin, Laura M. Yee, James H. Doroshow: The New NCI Precision Medicine Trials Clin Cancer Res : 2023.
Garcia-Manero G, Podoltsev NA, Othus M, Pagel JM, Radich JP, Fang M, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Kolitz JE, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Appelbaum FR, Erba HP.: A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia : 2023.
Academic Contact Information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-157
34th and Civic Center Blvd
Philadelphia,
PA
19104
Phone: 215-614-1847
Patient appointments: 800-789-7366